Nervonic acid composition for preventing neurodegenerative diseases and application of nervonic acid composition

Abstract

The invention relates to the technical field of drug delivery systems, in particular to a nervonic acid composition for preventing neurodegenerative diseases and application of the nervonic acid composition. The feed additive is prepared from the following raw materials in parts by weight: 8 to 12 parts of cis-15-tetracosenoic acid, 5 to 8 parts of N-acetylneuraminic acid, 3 to 6 parts of ganoderma triterpene, 1 to 3 parts of astaxanthin, 4 to 7 parts of rice bran fatty alkanol, 15 to 20 parts of modified soybean protein peptide, 8 to 12 parts of compound plant polyphenol and 6 to 10 parts of galactooligosaccharide. The rice bran fatty alkanol and nervonic acid form a complex ester to enhance the penetrability of the blood-brain barrier, the purity of nervonic acid in the composition is greater than or equal to 92%, the ester content is greater than or equal to 30%, the moisture is less than or equal to 2.5%, the particle size is 15-40 microns, and the oxidation induction period is greater than or equal to 120 hours. Through cooperation of multiple components, the bioavailability and stability of nervonic acid are improved, free radicals are removed, myelin sheaths are repaired, intestinal flora is adjusted, neurodegenerative diseases are prevented in a multi-target mode, and the effect is remarkable.

Description

Technical Field

[0001] The present invention relates to the technical field of drug delivery systems, and specifically to a neuraminic acid composition for preventing neurodegenerative diseases and its application. Background Art

[0002] Neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, characterized by progressive neuronal damage, demyelination, and cognitive decline, have become a major health challenge facing an aging world. According to statistics, the number of Alzheimer's patients worldwide exceeds 50 million, and the number is increasing annually, placing a heavy burden on families and society. The pathology of these diseases is complex, involving multiple factors such as oxidative stress, neuroinflammation, protein misfolding, and myelin structural disruption. Currently, there is no cure, making preventive intervention the key to reducing the risk of disease.

[0003] Among existing prevention strategies, single nutrient supplementation has obvious limitations. For example, although simple supplementation of neuraminic acid can promote myelin repair, it is highly lipid-soluble and has low bioavailability, making it difficult to penetrate the blood-brain barrier to exert its effects; antioxidants such as astaxanthin can scavenge free radicals, but they cannot improve the energy metabolism of nerve cells; probiotic preparations can regulate the intestinal flora-brain axis, but their direct protective effect on the central nervous system is limited. Clinical studies have shown that the occurrence of neurodegenerative diseases is related to the deficiency of multiple nutrients. For example, insufficient neuraminic acid can lead to myelin synthesis disorders, and the lack of plant polyphenols can aggravate oxidative stress. Single-ingredient intervention can often only target a certain pathological link, making it difficult to achieve multi-target synergistic prevention.

[0004] Traditional compositions mostly use a simple mixing process, lack synergy between active ingredients, and have poor stability. For example, neuraminic acid is easily oxidatively degraded, and the oxidative induction period is shortened to less than 48 hours after mixing with other ingredients; some fat-soluble ingredients have low solubility in aqueous environments and a bioavailability of less than 20%. In addition, existing products mostly focus on improving cognitive symptoms, ignoring upstream mechanisms such as intestinal flora balance and neuroinflammation regulation, and are unable to block disease progression at the source. Therefore, the development of a composition with multi-component synergy, high bioavailability, and multi-target intervention in neurodegenerative diseases has become an urgent need in current research. Summary of the Invention

[0005] (1) Technical problems solved In response to the deficiencies of the prior art, the present invention provides a neuraminic acid composition for preventing neurodegenerative diseases and its application. Technical Solution

[0006] A neuraminic acid composition for preventing neurodegenerative diseases comprises, by weight, 8-12 parts of cis-15-tetracosenoic acid, 5-8 parts of N-acetylneuraminic acid, 3-6 parts of ganoderma triterpenes, 1-3 parts of astaxanthin, 4-7 parts of rice bran fatty alkanols, 15-20 parts of modified soy protein peptides, 8-12 parts of composite plant polyphenols, and 6-10 parts of galacto-oligosaccharides. The rice bran fatty alkanols react with neuraminic acid to form a complex ester through an ester exchange reaction, thereby enhancing blood-brain barrier penetration. The neuraminic acid in the composition has a purity of ≥92%, an ester content of ≥30%, a moisture content of ≤2.5%, a particle size distribution of 15-40 μm, and an oxidation induction period of ≥120 hours.

[0007] Preferably, the composition further comprises 2-4 parts of salidroside with a purity of ≥98%, and a mass ratio of 1:2 to Ganoderma triterpenoids, which enhances the energy metabolism of nerve cells by activating the AMPK signaling pathway, and the solubility rate of salidroside in the composition is ≥90%.

[0008] Preferably, 0.8-1.5 parts of pyrroloquinoline quinone (PQQ) are further included, with a mass ratio of 1:3 to astaxanthin, to synergistically remove reactive oxygen species in the brain. The stability of PQQ in pH 7.0 buffer is ≥90% / 24h.

[0009] Preferably, the composite plant polyphenols are composed of blueberry anthocyanidins, green tea catechins, and grape skin proanthocyanidins in a mass ratio of 2:3:1, with a total phenol content of ≥85%, wherein the absorbance of anthocyanidins at 520 nm is ≥5.0, and the proportion of EGCG in catechins is ≥60%.

[0010] Preferably, the modified soybean protein peptide is hydrolyzed step by step by protease, with a hydrolysis degree of 25-30%, an average molecular weight of 500-800 Da, a nitrogen utilization rate of ≥92%, and a digestibility of ≥85% in simulated gastric fluid at 37°C.

[0011] Preferably, the polymerization degree of the galactoligosaccharide is 2-8, the purity is ≥90%, and the mass ratio of the galactoligosaccharide to the composite plant polyphenol is 1:1.2.

[0012] Preferably, the N-acetylneuraminic acid is prepared by freeze-drying method, has a purity of ≥95%, forms a 1:2 molecular complex with neuraminic acid, and the release rate of the complex in simulated cerebrospinal fluid is ≥80% / 6h.

[0013] Preferably, the excipients include 3-5 parts of hydroxypropyl methylcellulose and 2-4 parts of cross-linked polyvinylpyrrolidone, with a mass ratio of 3:2.

[0014] Preferably, add 0.5-1 portion of vitamin B 12 , with the mass ratio of rice bran fatty alkanol 1:8, participates in myelin synthesis through methyl transfer reaction, vitamin B 12 The retention rate in the composition is ≥95% / 6 months.

[0015] Preferably, the neuraminic acid composition for preventing neurodegenerative diseases is used to prepare an oral preparation for preventing Alzheimer's disease. The daily dose contains 220-280 mg of neuraminic acid and 150-200 mg of ester. Continuous use for 3 months can increase the neuraminic acid level in the subject's cerebrospinal fluid by ≥40%.

[0016] (3) Beneficial effects Compared with the existing technology, the beneficial effects of the present invention are: 1. The transesterification reaction between neuraminic acid and rice bran fatty alkanols forms a complex ester, which not only improves blood-brain barrier penetration but also prolongs the oxidative induction period, resolving the low bioavailability and susceptibility to oxidation of traditional neuraminic acid. Salidroside and Ganoderma triterpenes synergistically activate the AMPK signaling pathway, increasing ATP content in nerve cells and enhancing energy metabolism. The combination of astaxanthin and PQQ has an extremely high OH scavenging rate, significantly reducing oxidative stress damage. 2. The compound plant polyphenols and oligogalactose form a microecological regulation system, which can promote the proliferation of bifidobacteria 10 4 More than times, it reduces the level of pro-inflammatory factor IL-6 through the intestinal flora-brain axis; the digestibility of modified soy protein peptides is extremely high, providing sufficient nutritional substrate for nerve cells. Each component achieves multi-target synergy through intermolecular interactions: neuraminic acid repairs myelin, N-acetylneuraminic acid improves neurotransmitter transmission, and vitamin B 12 Promote methylation reactions and jointly block the cascade of neuronal damage; 3. The composition has excellent stability, with a disintegration time controlled at 3-5 minutes and a very high retention rate of active ingredients. A daily dose can increase the level of neuraminic acid in cerebrospinal fluid. Continuous intervention for 3 months can significantly improve cognitive function-related indicators, providing an efficient and safe new solution for the early prevention of neurodegenerative diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 is a bar graph comparing the in vitro release rate and oxidation induction period of nervonic acid in the examples and comparative examples; Figure 2 This is a bar graph comparing the neuraminic acid content in the brains of mice in the embodiment and the comparative example and the cognitive scores of the mice after 6 weeks; Figure 3 is a line graph comparing the blood-brain barrier penetration rate and the stability of the active ingredient of the embodiment and the comparative example; Figure 4 It is a bar graph comparing the oxidation induction period and the learning and memory improvement rate of mice in the embodiment and the comparative example. DETAILED DESCRIPTION

[0018] according to Figures 1 to 4 , the specific implementation of the present invention is as follows: Example 1: Standard Ratio Nervonic Acid Composition Raw materials and parameters By weight: cis-15-tetracosenoic acid (purity 92%, meeting the quality requirements of cis-15-tetracosenoic acid in Table 6-1) 10 parts, N-acetylneuraminic acid (purity 95%) 6 parts, ganoderma triterpenes (purity 85%) 4 parts, astaxanthin (purity 98%) 2 parts, rice bran fatty alkanol 5 parts, modified soybean protein peptide 18 parts (hydrolyzed by alkaline protease and flavor protease in two steps, degree of hydrolysis 28%), complex plant polyphenol 10 parts (blueberry anthocyanin: green tea catechin: grape skin proanthocyanidin = 2:3:1, total phenol content 86%), galactooligosaccharide 8 parts (polymerization degree 2-8, purity 91%); excipients are hydroxypropyl methylcellulose 4 parts, cross-linked polyvinylpyrrolidone 3 parts, vitamin B 12 0.8 parts. Preparation steps S1: Complex ester preparation: Mix rice bran fatty alkanol and nervonic acid at a mass ratio of 1:2, add 0.5% lipase (enzyme activity 1000 U / g), 60°C constant temperature water bath stirring reaction 4h, 45°C vacuum drying (vacuum degree-0.09MPa) to get esterification, high performance liquid chromatography detection esterification content 32%. S2: Mix and crush: Add esterification, N-acetylneuraminic acid, ganoderma triterpenes, astaxanthin, modified soybean protein peptide, complex plant polyphenol, and galactooligosaccharide into a three-dimensional mixer in turn, mix at 200 r / min for 30 min, crush to a particle size of 25 μm by a super micro pulverizer, and pass through an 80-mesh sieve (residue ≤1%). S3: Granulation and tabletting: Add hydroxypropyl methylcellulose, cross-linked polyvinylpyrrolidone, and vitamin B 12 , continue to mix for 30 min, prepare soft material with 30% ethanol as a binder, granulate with an 18-mesh sieve, dry at 60°C for 2h (moisture content ≤2.5%), and then tablet (diameter 6 mm, hardness 4 kgf) after sieving with a 16-mesh sieve. Performance test The oxidation induction period is 135h detected by GB / T 21121 method; the 6h nervonic acid release rate in simulated cerebrospinal fluid (pH 7.4) is 82% (high performance liquid chromatography method); the OH clearance rate is 96% detected by the autoxidation method of o-phenanthroline; the number of viable bifidobacteria is increased by 1.2×10 4 times (plate count method) after in vitro culture for 48h.

[0019] Example 2: High rhodioloside content composition Raw materials and parameters By weight: 10 parts of cis-15-tetracosenoic acid (purity 92%, in line with the quality requirements of cis-15-tetracosenoic acid in Table 6-1), 6 parts of N-acetylneuraminic acid (purity 95%), 4 parts of Ganoderma lucidum triterpenoids (purity 85%), 2 parts of astaxanthin (purity 98%), 5 parts of rice bran fatty alkyl alcohols, 18 parts of modified soybean protein peptides (hydrolyzed by alkaline protease and flavor protease, hydrolysis degree 28%), 10 parts of composite plant polyphenols (blueberry anthocyanidin: green tea catechin: grape skin proanthocyanidin = 2:3:1, total phenol content 86%), 8 parts of galacto-oligosaccharides (polymerization degree 2-8, purity 91%), 3 parts of salidroside (purity 98%, mass ratio with Ganoderma lucidum triterpenoids 1:1.3); excipients are 4 parts of hydroxypropyl methylcellulose, 3 parts of cross-linked polyvinylpyrrolidone, vitamin B 12 0.8 portion. Preparation steps S1: Preparation of complex ester: Rice bran fatty alkanol and nervonic acid were mixed in a mass ratio of 1:2, 0.5% lipase (enzyme activity 1000 U / g) was added, and the mixture was stirred in a constant temperature water bath at 60°C for 4 h. The mixture was dried under vacuum at 45°C (vacuum degree -0.09 MPa) to obtain the ester. The ester content was 31% as determined by HPLC. S2: Mixing and grinding: premix salidroside and Ganoderma lucidum triterpenoids for 10 minutes, then add esterification product, N-acetylneuraminic acid, astaxanthin, modified soy protein peptide, compound plant polyphenols and oligogalactose into three-dimensional mixer in sequence, mix at 200r / min for 30 minutes, grind to particle size of 24μm by ultrafine grinder, and pass through 80 mesh sieve (sieve residue ≤1%). S3: Granulation and tableting: Add hydroxypropyl methylcellulose, cross-linked polyvinylpyrrolidone, and vitamin B 12 , continue mixing for 40 minutes, use 30% ethanol as a binder to make a soft material, sieve 18 mesh to granulate, dry with forced air at 60℃ for 2 hours (moisture ≤ 2.5%), sieve 16 mesh to size the granules and press into tablets (diameter 6mm, hardness 3.8kgf). Performance Testing The oxidative induction period was 130 hours using the GB / T 21121 method. The release rate of neuraminic acid in simulated cerebrospinal fluid (pH 7.4) was 80% after 6 hours (HPLC). The OH clearance rate was 95% as measured by the pyrogallol autooxidation method. The ATP content in neurons was increased by 45% compared with the blank group (luciferin-luciferase method). After 48 hours of in vitro culture, the number of viable bifidobacteria increased by 1.1×10-1, compared with the initial count. 4 times (plate count method). Example 3: High PQQ Content Composition Raw materials and parameters By weight: 10 parts of cis-15-tetracosenoic acid (purity 92%, in line with the quality requirements of cis-15-tetracosenoic acid in Table 6-1), 6 parts of N-acetylneuraminic acid (purity 95%), 4 parts of Ganoderma lucidum triterpenes (purity 85%), 2 parts of astaxanthin (purity 98%), 5 parts of rice bran fatty alkyl alcohols, 18 parts of modified soybean protein peptides (hydrolyzed by alkaline protease and flavor protease, hydrolysis degree 28%), 10 parts of composite plant polyphenols (blueberry anthocyanin: green tea catechin: grape skin proanthocyanidin = 2:3:1, total phenol content 86%), 8 parts of galacto-oligosaccharides (polymerization degree 2-8, purity 91%), 1.2 parts of pyrroloquinoline quinone (PQQ) (purity 99%, mass ratio with astaxanthin 1:1.7); excipients are 4 parts of hydroxypropyl methylcellulose, 3 parts of cross-linked polyvinylpyrrolidone, and vitamin B 12 0.8 portion. Preparation steps S1: Preparation of complex ester: Rice bran fatty alkanol and nervonic acid were mixed in a mass ratio of 1:2, 0.5% lipase (enzyme activity 1000 U / g) was added, and the mixture was stirred in a constant temperature water bath at 60°C for 4 h. The mixture was dried under vacuum at 45°C (vacuum degree -0.09 MPa) to obtain the ester. The ester content was 33% as determined by HPLC. S2: Mixed grinding: The esterified product, N-acetylneuraminic acid, Ganoderma lucidum triterpenes, modified soy protein peptides, compound plant polyphenols and oligogalactose were added to the three-dimensional mixer in sequence. PQQ and astaxanthin were dissolved in a small amount of ethanol (concentration 5%). After ultrasonic dispersion for 10 minutes, the mixture was sprayed into the mixed system. The mixture was mixed at 200 r / min for 30 minutes. The mixture was ground into a particle size of 26 μm using an ultrafine grinder and passed through an 80-mesh sieve (the residue on the sieve was ≤1%). S3: Granulation and tableting: Add hydroxypropyl methylcellulose, cross-linked polyvinylpyrrolidone, and vitamin B 12 , continue mixing for 30 minutes, use 30% ethanol as a binder to make a soft material, sieve 18 mesh to granulate, dry with air at 60℃ for 2 hours (moisture ≤ 2.5%), sieve 16 mesh to size the granules and press into tablets (diameter 6mm, hardness 4.2kgf). Performance Testing The oxidative induction period was 140 hours using the GB / T 21121 method. The neuraminic acid release rate in simulated cerebrospinal fluid (pH 7.4) was 83% after 6 hours (HPLC). The OH clearance rate was 98% as measured by the pyrogallol autoxidation method. The PQQ stability was 92% after 24 hours (HPLC). After 48 hours of in vitro culture, the number of viable bifidobacteria increased by 1.2×10 compared to the initial count. 4 times (plate count method). Example 4: Optimizing the galacto-oligosaccharide ratio composition Raw materials and parameters By weight: 10 parts of cis-15-tetracosenoic acid (purity 92%, in line with the quality requirements of cis-15-tetracosenoic acid in Table 6-1), 6 parts of N-acetylneuraminic acid (purity 95%), 4 parts of Ganoderma lucidum triterpenes (purity 85%), 2 parts of astaxanthin (purity 98%), 5 parts of rice bran fatty alkyl alcohols, 18 parts of modified soybean protein peptides (hydrolyzed by alkaline protease and flavor protease, hydrolysis degree 28%), 10 parts of composite plant polyphenols (blueberry anthocyanin: green tea catechin: grape skin proanthocyanidin = 2:3:1, total phenol content 86%), 10 parts of oligosaccharides (polymerization degree 2-8, purity 91%, mass ratio with composite plant polyphenols 1:1); excipients are 4 parts of hydroxypropyl methylcellulose, 3 parts of cross-linked polyvinylpyrrolidone, and vitamin B 12 0.8 portion. Preparation steps S1: Preparation of complex ester: Rice bran fatty alkanol and nervonic acid were mixed in a mass ratio of 1:2, 0.5% lipase (enzyme activity 1000 U / g) was added, and the mixture was stirred in a constant temperature water bath at 60°C for 4 h. The mixture was dried under vacuum at 45°C (vacuum degree -0.09 MPa) to obtain the ester. The ester content was 32% as determined by HPLC. S2: Mixing and grinding: add the esterified product, N-acetylneuraminic acid, Ganoderma lucidum triterpenes, astaxanthin, modified soy protein peptide, compound plant polyphenols and 60% galacto-oligosaccharide into a three-dimensional mixer in sequence, mix at 200 r / min for 20 min, add the remaining 40% galacto-oligosaccharide and continue mixing for 10 min, grind into a particle size of 25 μm using an ultrafine grinder, and pass through an 80-mesh sieve (the residue on the sieve is ≤1%). S3: Granulation and tableting: Add hydroxypropyl methylcellulose, cross-linked polyvinylpyrrolidone, and vitamin B 12 , continue mixing for 30 minutes, use 30% ethanol as a binder to make a soft material, sieve 18 mesh to granulate, dry with forced air at 60℃ for 2 hours (moisture ≤ 2.5%), sieve 16 mesh to size the granules and press into tablets (diameter 6mm, hardness 4.0kgf). Performance Testing The oxidative induction period was 132 hours using the GB / T 21121 method. The release rate of neuraminic acid in simulated cerebrospinal fluid (pH 7.4) was 81% over 6 hours (HPLC). The OH clearance rate was 96% as measured by the pyrogallol autoxidation method. The retention rate of the composite plant polyphenols was 90% (Folin-phenol method). After 48 hours of in vitro culture, the number of viable bifidobacteria increased by 1.5×10-10 compared to the initial count. 4 times (plate count method).

[0020] Comparative Example: Single Nervonic Acid Composition Raw materials and parameters By weight: 10 parts of cis-15-tetracosenoic acid, 30 parts of microcrystalline cellulose, 1 part of magnesium stearate, no other active ingredients.

[0021] Preparation steps S1: Add nervonic acid, microcrystalline cellulose and magnesium stearate into a mixer, mix at 150 r / min for 20 min, and grind to a particle size of 30 μm.

[0022] S2: Direct compression (6 mm diameter, 3.5 kgf hardness).

[0023] Performance Testing The oxidative induction period was 45 hours; the 6-hour neuraminic acid release rate in the simulated cerebrospinal fluid was 35%; the OH clearance rate was 20%; there was no significant increase in the number of viable bifidobacteria (P>0.05); and the nerve cell activity was increased by 10% compared with the blank group.

[0024] The core performance parameters of the embodiment and the comparative example are shown in the following table:

[0025] Summary: The performance of Examples 1-4 is significantly better than that of the control example. The in vitro release rate of neuraminic acid is 80%-83% over 6 hours, far exceeding the 35% of the control example; the oxidation induction period is 130-140 hours, nearly 3 times that of the 45 hours of the control example. In animal experiments, the content of neuraminic acid in the brain of mice in the examples is 27.9-29.3 μg / g, which is 2.7 times that of the 10.5 μg / g of the control example. After 6 weeks, the Morris water maze cognitive score is 33.5-36.8s, which is significantly lower than the 58.3s of the control example, indicating that the examples have obvious synergistic effects.

[0026] The synergistic effect of the active ingredients in the examples and comparative examples is verified as shown in the following table:

[0027] In summary, Examples 1-4 achieved blood-brain barrier penetration rates 2.7-2.9 times higher than those of the control group, 48-hour active ingredient stability 1.9-2 times higher, and significantly higher learning and memory improvement rates. Example 3 achieved the best performance across all three metrics, demonstrating its advantages in targeted delivery and sustained efficacy, further demonstrating that the composite formulation far surpasses single-ingredient compositions in multiple performance areas.

[0028] While embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the invention, and that the scope of the invention is defined by the appended claims and their equivalents.

Claims

1. A neuraminic acid composition for preventing neurodegenerative diseases, characterized in that: The raw materials include, by weight, 8-12 parts of cis-15-tetracosenoic acid, 5-8 parts of N-acetylneuraminic acid, 3-6 parts of ganoderma triterpenes, 1-3 parts of astaxanthin, 4-7 parts of rice bran fatty alkanols, 15-20 parts of modified soybean protein peptides, 8-12 parts of complex plant polyphenols, and 6-10 parts of oligogalactose. The rice bran fatty alkanols and neuraminic acid form complex esters through an ester exchange reaction, thereby enhancing blood-brain barrier permeability. The neuraminic acid in the composition has a purity of ≥92%, an ester content of ≥30%, a moisture content of ≤2.5%, a particle size distribution of 15-40 μm, and an oxidation induction period of ≥120 hours.

2. The neuraminic acid composition for preventing neurodegenerative diseases according to claim 1, characterized in that It also includes 2-4 parts of salidroside with a purity of ≥98%, and a mass ratio of 1:2 with Ganoderma lucidum triterpenes. It enhances the energy metabolism of nerve cells by activating the AMPK signaling pathway, and the solubility rate of salidroside in the composition is ≥90%.

3. The neuraminic acid composition for preventing neurodegenerative diseases according to claim 1, characterized in that It also includes 0.8-1.5 parts of pyrroloquinoline quinone PQQ, with a mass ratio of 1:3 to astaxanthin, which synergistically removes reactive oxygen species in the brain. The stability of PQQ in pH 7.0 buffer is ≥90% / 24h.

4. The neuraminic acid composition for preventing neurodegenerative diseases according to claim 1, characterized in that The composite plant polyphenols are composed of blueberry anthocyanidins, green tea catechins, and grape skin proanthocyanidins in a mass ratio of 2:3:1, with a total phenol content of ≥85%, wherein the absorbance of anthocyanidins at 520 nm is ≥5.0, and the proportion of EGCG in catechins is ≥60%.

5. The neuraminic acid composition for preventing neurodegenerative diseases according to claim 1, characterized in that The modified soybean protein peptide is hydrolyzed step by step by protease, with a hydrolysis degree of 25-30%, an average molecular weight of 500-800 Da, a nitrogen utilization rate of ≥92%, and a digestibility of ≥85% in simulated gastric fluid at 37°C.

6. The neuraminic acid composition for preventing neurodegenerative diseases according to claim 1, characterized in that The polymerization degree of the oligogalactose is 2-8, the purity is ≥90%, and the mass ratio of the oligogalactose to the composite plant polyphenol is 1:1.

2.

7. The neuraminic acid composition for preventing neurodegenerative diseases according to claim 1, characterized in that The N-acetylneuraminic acid is prepared by freeze-drying method, has a purity of ≥95%, and forms a 1:2 molecular complex with neuraminic acid. The release rate of the complex in simulated cerebrospinal fluid is ≥80% / 6h.

8. The neuraminic acid composition for preventing neurodegenerative diseases according to claim 1, characterized in that The auxiliary materials include 3-5 parts of hydroxypropyl methylcellulose and 2-4 parts of cross-linked polyvinylpyrrolidone, with a mass ratio of 3:

2.

9. The neuraminic acid composition for preventing neurodegenerative diseases according to claim 1, characterized in that: Add 0.5-1 serving of vitamin B 12 , with the mass ratio of rice bran fatty alkanol 1:8, participates in myelin synthesis through methyl transfer reaction, vitamin B 12 The retention rate in the composition is ≥95% / 6 months.

10. Use of the neuraminic acid composition for preventing neurodegenerative diseases according to any one of claims 1 to 9, characterized in that: Used to prepare an oral preparation for preventing Alzheimer's disease, the daily dose contains 220-280 mg of neuraminic acid and 150-200 mg of ester. Continuous use for 3 months can increase the level of neuraminic acid in the cerebrospinal fluid of the subject by ≥40%.

Images